Coping motives mediate the relationship between PTSD and MDMA use in adolescents with substance use disorders
Lukas Andreas Basedow, Melina Felicitas Wiedmann, Veit Roessner, Yulia Golub, Sören Kuitunen-Paul
Addiction Science & Clinical Practice September 4, 2022 DOI: 10.1186/s13722-022-00329-y (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional study Peer reviewed |
|---|---|
| Sample size | 111 |
| Population | German adolescent SUD patients aged 13–18 years at an outpatient clinic |
| Topics | Addiction MDMA PTSD |
| Keywords | Drugs Self-medication Trauma disorders |
| Citations | 17 |
| Key findings | Adolescent SUD patients with current PTSD showed higher past-year MDMA use than those without trauma or with trauma but no PTSD, an association partially mediated by coping motives. |
Abstract
Abstract Background Post-traumatic stress disorder (PTSD) and substance use disorders (SUDs) often co-occur in adolescent patients. Previous research has shown that these patients differ from SUD patients without PTSD in terms of their substance use patterns. In this study, we aimed to test whether substance use in this population is related to an attempt to self-medicate PTSD-related symptoms.
Methods: German adolescent patients (aged 13–18 years) at an outpatient clinic for SUD treatment, n = 111 (43% female), completed a self-designed questionnaire on use motives, a measure of PTSD-related experiences, and underwent a standardized psychiatric interview including structured substance use questions. Participants were subsequently classified as ‘no traumatic experiences (‘noTEs’ but SUD), ‘traumatic experiences but no current PTSD diagnosis’ (‘TEs’ with SUD), and ‘PTSD’ with SUD. After establishing a self-designed motive measurement through exploratory and confirmatory factor analyses, we calculated non-parametric group differences and a mediation analysis in a linear regression framework.
Results: The past-year frequency of MDMA use was highest in the PTSD group and lowest in the noTE group (H (2) = 7.2, p = .027, η 2 = .058), but no differences were found for frequencies of tobacco, alcohol, cannabis, or stimulant use (all H ≤ 4.9, p ≥ .085, η 2 ≤ .033). While controlling for sex, the three groups showed a similar pattern (highest in the PTSD group and lowest in the noTE group) for coping scores (F (103) = 5.77, p = .004, η 2 = .101). Finally, mediation analyses revealed an indirect effect of coping score (b = 0.61, 95% CI [0.29, 1.58], p = .145) on the association between group membership and MDMA use frequency.
Conclusions: In adolescent SUD patients, we found an association of current PTSD and lifetime traumatic experiences with higher MDMA use that could be partially explained by substance use being motivated by an attempt to cope with mental health symptoms. This indicates a coping process involved specifically in MDMA use compared to the use of other psychoactive substances, possibly due to unique psychoactive effects of MDMA.
Comparable studies
Other cross-sectional and survey studies on MDMA for addiction, most cited first.
Citations in the library
Cited by 7
- MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations. European Child & Adolescent Psychiatry November 1, 2024
- Women and MDMA: particularities of gender and sex. International Review of Psychiatry 2023
- Prevalence and Correlates of Lifetime Ecstasy/MDMA Use Among Asian American and Pacific Islander Adult Populations in the United States, 2015–2020 Journal of Psychoactive Drugs March 3, 2025
- Lifetime MDMA use and associations with meaning in life in the context of childhood trauma Scientific Reports February 10, 2026
- The effects of acute and repeated adolescent MDMA exposure on behavior, cognition, and the monoamine neurotransmitter systems: A review of human and pre-clinical research Behavioural Brain Research February 10, 2026
and 2 more in the library
Cites 9
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
- A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy Frontiers in Psychiatry March 20, 2019
- Ecstasy (MDMA) dependence Drug and Alcohol Dependence January 7, 1999
- Sub-acute effects of MDMA (±3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences Psychopharmacology April 1, 2002
and 4 more in the library